

Lale S Tokgzoglu

List of Publications by Citations

Source: <https://exaly.com/author-pdf/689597/lale-s-tokgozoglu-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

87
papers

16,449
citations

37
h-index

104
g-index

104
ext. papers

22,820
ext. citations

5
avg, IF

5.87
L-index

#	Paper	IF	Citations
87	2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. <i>European Heart Journal</i> , 2020 , 41, 111-188	9.5	2236
86	ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). <i>European Heart Journal</i> , 2011 , 32, 1769-818	9.5	2020
85	2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. <i>European Heart Journal</i> , 2016 , 37, 2999-3058	9.5	1781
84	Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. <i>European Heart Journal</i> , 2017 , 38, 2459-2472	9.5	1267
83	Lipoprotein(a) as a cardiovascular risk factor: current status. <i>European Heart Journal</i> , 2010 , 31, 2844-53	9.5	1100
82	Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. <i>European Heart Journal</i> , 2011 , 32, 1345-61	9.5	793
81	Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. <i>European Heart Journal</i> , 2015 , 36, 1012-22	9.5	770
80	European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2007 , 14 Suppl 2, S1-113		751
79	Atherosclerosis. <i>Nature Reviews Disease Primers</i> , 2019 , 5, 56	51.1	657
78	EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. <i>European Journal of Preventive Cardiology</i> , 2016 , 23, 636-48	3.9	549
77	2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). <i>Atherosclerosis</i> , 2016 , 253, 281-344	3.1	519
76	2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. <i>European Heart Journal</i> , 2021 , 42, 3227-3337	9.5	358
75	Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk). <i>Circulation</i> , 2018 , 137, 338-350	16.7	348
74	Plant sterols and plant stanols in the management of dyslipidaemia and prevention of cardiovascular disease. <i>Atherosclerosis</i> , 2014 , 232, 346-60	3.1	330
73	European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2007 , 14 Suppl 2, S1-113		309
72	Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. <i>European Heart Journal</i> , 2020 , 41, 2313-2330	9.5	301
71	Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry. <i>European Journal of Preventive Cardiology</i> , 2019 , 26, 824-835	3.9	288

70	2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. <i>Atherosclerosis</i> , 2019 , 290, 140-205	3.1	259
69	Adverse effects of statin therapy: perception vs. the evidence - focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract. <i>European Heart Journal</i> , 2018 , 39, 2526-2539	9.5	156
68	2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia. <i>European Heart Journal</i> , 2018 , 39, 1131-1143	9.5	132
67	Impact of Lipids on Cardiovascular Health: JACC Health Promotion Series. <i>Journal of the American College of Cardiology</i> , 2018 , 72, 1141-1156	15.1	126
66	Management of dyslipidaemia in patients with coronary heart disease: Results from the ESC-EORP EUROASPIRE V survey in 27 countries. <i>Atherosclerosis</i> , 2019 , 285, 135-146	3.1	106
65	European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk. <i>European Heart Journal</i> , 2017 , 38, 2245-2255	9.5	105
64	Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). <i>Atherosclerosis</i> , 2018 , 277, 234-255	3.1	93
63	Reducing the Clinical and Public Health Burden of Familial Hypercholesterolemia: A Global Call to Action. <i>JAMA Cardiology</i> , 2020 , 5, 217-229	16.2	85
62	Patients with coronary artery disease and diabetes need improved management: a report from the EUROASPIRE IV survey: a registry from the EuroObservational Research Programme of the European Society of Cardiology. <i>Cardiovascular Diabetology</i> , 2015 , 14, 133	8.7	74
61	The selective peroxisome proliferator-activated receptor alpha modulator (SPPARM) paradigm: conceptual framework and therapeutic potential : A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation. <i>Cardiovascular Diabetology</i> , 2019 , 18, 71	8.7	64
60	The use of statins in people at risk of developing diabetes mellitus: evidence and guidance for clinical practice. <i>Atherosclerosis Supplements</i> , 2014 , 15, 1-15	1.7	62
59	The gender gap in risk factor control: Effects of age and education on the control of cardiovascular risk factors in male and female coronary patients. The EUROASPIRE IV study by the European Society of Cardiology. <i>International Journal of Cardiology</i> , 2016 , 209, 284-90	3.2	57
58	Trends in Gender Differences in Cardiac Care and Outcome After Acute Myocardial Infarction in Western Sweden: A Report From the Swedish Web System for Enhancement of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies (SWEDEHEART). <i>Journal of the American Heart Association</i> , 2015 , 4,	6	55
57	PCSK9 inhibition and inflammation: A narrative review. <i>Atherosclerosis</i> , 2019 , 288, 146-155	3.1	52
56	Obesity and cardiovascular risk: a call for action from the European Society of Hypertension Working Group of Obesity, Diabetes and the High-risk Patient and European Association for the Study of Obesity: part A: mechanisms of obesity induced hypertension, diabetes and dyslipidemia and practice guidelines for treatment. <i>Journal of Hypertension</i> , 2018 , 36, 1427-1440	1.9	48
55	Rare dyslipidaemias, from phenotype to genotype to management: a European Atherosclerosis Society task force consensus statement. <i>Lancet Diabetes and Endocrinology</i> , 2020 , 8, 50-67	18.1	48
54	European Heart Rhythm Association (EHRA)/European Association of Cardiovascular Prevention and Rehabilitation (EACPR) position paper on how to prevent atrial fibrillation endorsed by the Heart Rhythm Society (HRS) and Asia Pacific Heart Rhythm Society (APHRS). <i>European Journal of Preventive Cardiology</i> , 2017 , 24, 4-40	3.9	43
53	Atrial fibrillation after coronary artery bypass surgery: predictors and the role of MgSO4 replacement. <i>Journal of Cardiac Surgery</i> , 1996 , 11, 421-7	1.3	43

52	Effects of persistent atrial fibrillation on serum galectin-3 levels. <i>American Journal of Cardiology</i> , 2015 , 115, 647-51	3	42
51	Plasma interleukin-6 levels are increased in coronary artery ectasia. <i>Acta Cardiologica</i> , 2004 , 59, 515-9	0.9	42
50	Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society. <i>European Heart Journal</i> , 2021 ,	9.5	35
49	Guñ ESC/EAS 2016 sobre el tratamiento de las dislipemias. <i>Revista Espanola De Cardiologia</i> , 2017 , 70, 115.e1-115.e64	1.5	22
48	Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: A statement from a European Atherosclerosis Society Task Force. <i>Atherosclerosis</i> , 2021 , 325, 99-109	3.1	22
47	A nation-wide survey of patients with homozygous familial hypercholesterolemia phenotype undergoing LDL-apheresis in Turkey (A-HIT 1 registry). <i>Atherosclerosis</i> , 2018 , 270, 42-48	3.1	20
46	Prevalence of potential familial hypercholesteremia (FH) in 54,811 statin-treated patients in clinical practice. <i>Atherosclerosis</i> , 2016 , 252, 1-8	3.1	20
45	The association between circulating endothelial progenitor cells and coronary collateral formation. <i>Atherosclerosis</i> , 2011 , 219, 851-4	3.1	18
44	Functional exercise capacity, physical activity, and respiratory and peripheral muscle strength in pulmonary hypertension according to disease severity. <i>Journal of Physical Therapy Science</i> , 2015 , 27, 1309-12	1	16
43	Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). <i>Lancet, The</i> , 2021 , 398, 1713-1725	4.0	14
42	Atherosclerotic vascular disease and risk factors in Turkey: from past to present. <i>Journal of Atherosclerosis and Thrombosis</i> , 2008 , 15, 286-91	4	13
41	New cardiovascular prevention guidelines: How to optimally manage dyslipidaemia and cardiovascular risk in 2021 in patients needing secondary prevention?. <i>Atherosclerosis</i> , 2021 , 319, 51-61	3.1	12
40	Percentage low-density lipoprotein-cholesterol response to a given statin dose is not fixed across the pre-treatment range: Real world evidence from clinical practice: Data from the ESC-EORP EUROASPIRE V Study. <i>European Journal of Preventive Cardiology</i> , 2020 , 27, 1630-1636	3.9	11
39	Combination lipid-lowering therapy as first-line strategy in very high-risk patients. <i>European Heart Journal</i> , 2021 ,	9.5	11
38	Pulmonary hypertension in Takayasu arteritis. <i>International Journal of Rheumatic Diseases</i> , 2018 , 21, 1634-1639	11	
37	What have we learned from Turkish familial hypercholesterolemia registries (A-HIT1 and A-HIT2)?. <i>Atherosclerosis</i> , 2018 , 277, 341-346	3.1	10
36	Clinical management, psychosocial characteristics, and quality of life in patients with homozygous familial hypercholesterolemia undergoing LDL-apheresis in Turkey: Results of a nationwide survey (A-HIT1 registry). <i>Journal of Clinical Lipidology</i> , 2019 , 13, 455-467	4.9	9
35	New prospects for PCSK9 inhibition?. <i>European Heart Journal</i> , 2018 , 39, 2600-2601	9.5	9

34	Reprint of: Impact of Lipids on Cardiovascular Health: JACC Health Promotion Series. <i>Journal of the American College of Cardiology</i> , 2018 , 72, 2980-2995	15.1	9
33	Cost of heart failure management in Turkey: results of a Delphi Panel. <i>Anatolian Journal of Cardiology</i> , 2016 , 16, 554-62	0.8	7
32	Implementation, target population, compliance and barriers to risk guided therapy. <i>European Journal of Preventive Cardiology</i> , 2012 , 19, 37-41	3.9	6
31	Familial Hypercholesterolemia: Global Burden and Approaches. <i>Current Cardiology Reports</i> , 2021 , 23, 151	4.2	6
30	Pre- and in-hospital antithrombotic management patterns and in-hospital outcomes in patients with acute coronary syndrome: data from the Turkish arm of the EPICOR study. <i>Anatolian Journal of Cardiology</i> , 2016 , 16, 900-915	0.8	5
29	Taking action: European Atherosclerosis Society targets the United Nations Sustainable Development Goals 2030 agenda to fight atherosclerotic cardiovascular disease in Europe. <i>Atherosclerosis</i> , 2021 , 322, 77-81	3.1	5
28	Lipid-lowering and anti-thrombotic therapy in patients with peripheral arterial disease. <i>Vasa - European Journal of Vascular Medicine</i> , 2021 , 50, 401-411	1.9	4
27	Patient characteristics and statin discontinuation-related factors during treatment of hypercholesterolemia: an observational non-interventional study in patients with statin discontinuation (STAY study). <i>Turk Kardiyoloji Dernegi Arsivi</i> , 2016 , 44, 53-64		4
26	The landscape of preventive cardiology in Turkey: Challenges and successes. <i>American Journal of Preventive Cardiology</i> , 2021 , 6, 100184	1.9	4
25	Medical Treatment in Coronary Patients: Is there Still a Gender Gap? Results from European Society of Cardiology EUROASPIRE V Registry. <i>Cardiovascular Drugs and Therapy</i> , 2021 , 35, 801-808	3.9	3
24	Diet, Lifestyle, Smoking. <i>Handbook of Experimental Pharmacology</i> , 2020 , 1	3.2	3
23	The functional and structural evaluation of small fibers in asymptomatic carriers of p.Val50Met (Val30Met) mutation.. <i>Neuromuscular Disorders</i> , 2021 ,	2.9	3
22	Anti-Hyperglycemic Agents for the Treatment of Type 2 Diabetes Mellitus: Role in Cardioprotection During the Last Decade. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , 2017 , 17, 19-31	2.2	3
21	Lipid Clinics Network. Rationale and design of the EAS global project. <i>Atherosclerosis Supplements</i> , 2020 , 42, e6-e8	1.7	3
20	Association of dietary and gut microbiota-related metabolites with calcific aortic stenosis. <i>Acta Cardiologica</i> , 2021 , 76, 544-552	0.9	3
19	Mental status and physical activity in patients with homozygous familial hypercholesterolemia: A subgroup analysis of a nationwide survey (A-HIT1 registry). <i>Journal of Clinical Lipidology</i> , 2020 , 14, 361-370.e2	4.9	2
18	The year in cardiovascular medicine 2021: dyslipidaemia.. <i>European Heart Journal</i> , 2022 ,	9.5	2
17	Snapshot evaluation of acute and chronic heart failure in real-life in Turkey: A follow-up data for mortality. <i>Anatolian Journal of Cardiology</i> , 2020 , 23, 160-168	0.8	2

16	Transatlantic Lipid Guideline Divergence: Same Data But Different Interpretations. <i>Journal of the American Heart Association</i> , 2020 , 9, e018189	6	2
15	Redefining cardiovascular risk prediction: is the crystal ball clearer now?. <i>European Heart Journal</i> , 2021 , 42, 2468-2471	9.5	2
14	Is there a gender gap in secondary prevention of coronary artery disease in Turkey?. <i>Türk Kardiyoloji Dernegi Arsivi</i> , 2018 , 46, 683-691	0.3	2
13	Should We Target Global Risk or Risk Factors?. <i>Current Atherosclerosis Reports</i> , 2021 , 23, 2	6	1
12	Current perceptions and practices in lipid management: results of a European Society of Cardiology/European Atherosclerosis Society Survey. <i>European Journal of Preventive Cardiology</i> , 2021 ,	3.9	1
11	Correlation of tissue selectin expression and hemodynamic parameters in rheumatic mitral valve disease. <i>Journal of Heart Valve Disease</i> , 2006 , 15, 671-8		1
10	Lipid-lowering and anti-thrombotic therapy in patients with peripheral arterial disease: European Atherosclerosis Society/European Society of Vascular Medicine Joint Statement. <i>Atherosclerosis</i> , 2021 , 338, 55-63	3.1	0
9	Similarities and differences between European and American guidelines on the management of blood lipids to reduce cardiovascular risk. <i>Atherosclerosis Supplements</i> , 2020 , 42, e1-e5	1.7	0
8	In-hospital statin initiation characteristics and one-year statin adherence rates in patients hospitalised for acute coronary syndrome. <i>Acta Cardiologica</i> , 2021 , 76, 852-858	0.9	0
7	Cholesterol efflux promoting function of high-density lipoproteins in calcific aortic valve stenosis. <i>Atherosclerosis Plus</i> , 2021 , 44, 18-18		0
6	Evaluation of internal medicine physicians' attitudes toward the treatment of dyslipidemia. <i>Postgraduate Medicine</i> , 2020 , 132, 538-543	3.7	
5	Successful pregnancy by in vitro fertilization after Mustard operation for transposition of the great arteries. <i>Journal of Cardiology Cases</i> , 2011 , 3, e50-e52	0.6	
4	How did the updated hemodynamic definitions affect the frequency of pulmonary hypertension in patients with systemic sclerosis?. <i>Anatolian Journal of Cardiology</i> , 2021 , 25, 30-35	0.8	
3	An updated perspective and pooled analysis of cardiovascular outcome trials of GLP-1 receptor agonists and SGLT-2 inhibitors. <i>Anatolian Journal of Cardiology</i> , 2021 , 25, 61-76	0.8	
2	Which patients have the highest cardiovascular risk? A follow-up study from Turkey. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2005 , 12, 250-6		
1	Demographics of patients with heart failure who were over 80 years old and were admitted to the cardiology clinics in Turkey. <i>Anatolian Journal of Cardiology</i> , 2019 , 21, 196-205	0.8	